Neutrophil Resolvin E1 Receptor Expression and Function in Type 2 Diabetes
暂无分享,去创建一个
[1] J. Baddley,et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial , 2016, The Lancet.
[2] M. Hersberger,et al. ChemR23, the Receptor for Chemerin and Resolvin E1, Is Expressed and Functional on M1 but Not on M2 Macrophages , 2015, The Journal of Immunology.
[3] B. Levy,et al. Lipid mediators in the resolution of inflammation. , 2015, Cold Spring Harbor perspectives in biology.
[4] A. Kantarcı,et al. Impact of Resolvin E1 on Murine Neutrophil Phagocytosis in Type 2 Diabetes , 2014, Infection and Immunity.
[5] C. Serhan,et al. Aging Delays Resolution of Acute Inflammation in Mice: Reprogramming the Host Response with Novel Nano-Proresolving Medicines , 2014, The Journal of Immunology.
[6] Charles N. Serhan,et al. Pro-resolving lipid mediators are leads for resolution physiology , 2014, Nature.
[7] C. Serhan,et al. Lipoxin A4 modulates adaptive immunity by decreasing memory B‐cell responses via an ALX/FPR2‐dependent mechanism , 2014, European journal of immunology.
[8] M. Perretti,et al. Chemerin15 inhibits neutrophil-mediated vascular inflammation and myocardial ischemia-reperfusion injury through ChemR23 , 2013, EMBO reports.
[9] T. E. Dyke,et al. RvE1 and phagocytosis of Porphyromonas gingivalis by PMN in type 2 diabetes (P4227) , 2013 .
[10] Gun-Dong Kim,et al. Omega-3 fatty acid-derived mediator, Resolvin E1, ameliorates 2,4-dinitrofluorobenzene-induced atopic dermatitis in NC/Nga mice. , 2012, International immunopharmacology.
[11] C. Serhan,et al. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. , 2012, Blood.
[12] Trevor A. Mori,et al. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. , 2012, Clinical chemistry.
[13] G. Hajishengallis,et al. The keystone-pathogen hypothesis , 2012, Nature Reviews Microbiology.
[14] J. Filep,et al. Resolvin E1 promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation , 2012, Proceedings of the National Academy of Sciences.
[15] C. Serhan,et al. Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[16] David Whiting,et al. The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults. , 2011, Diabetes research and clinical practice.
[17] C. Serhan,et al. Saturated‐efferocytosis generates pro‐resolving CD11blow macrophages: Modulation by resolvins and glucocorticoids , 2011, European journal of immunology.
[18] Charles N Serhan,et al. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions , 2010, Nature Medicine.
[19] Ping Li,et al. Metabolism: Host and microbes in a pickle , 2010, Nature.
[20] T. Azuma,et al. Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium–induced colitis , 2008, Inflammatory bowel diseases.
[21] C. Serhan,et al. Resolvin E1 Receptor Activation Signals Phosphorylation and Phagocytosis* , 2009, The Journal of Biological Chemistry.
[22] M. Perretti,et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis , 2009, Nature.
[23] T. Ishizuka,et al. Resolvin E1: a novel lipid mediator in the resolution of allergic airway inflammation , 2008, Expert review of clinical immunology.
[24] K. Kornman,et al. Inflammation and factors that may regulate inflammatory response. , 2008, Journal of periodontology.
[25] B. Levy,et al. Resolvin E1 regulates interleukin 23, interferon-γ and lipoxin A4 to promote the resolution of allergic airway inflammation , 2008, Nature Immunology.
[26] Charles N. Serhan,et al. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators , 2008, Nature Reviews Immunology.
[27] T. Ishizuka,et al. Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. , 2008, Biochemical and biophysical research communications.
[28] Yan Lu,et al. Resolvin E1 Metabolome in Local Inactivation during Inflammation-Resolution1 , 2008, The Journal of Immunology.
[29] C. Andry,et al. Resolvin E1 Regulates Inflammation at the Cellular and Tissue Level and Restores Tissue Homeostasis In Vivo1 , 2007, The Journal of Immunology.
[30] C. Serhan,et al. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[31] Lois E. H. Smith,et al. Increased dietary intake of ω-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis , 2007, Nature Medicine.
[32] Charles N. Serhan,et al. Resolvin E1 and protectin D1 activate inflammation-resolution programmes , 2007, Nature.
[33] Charles N. Serhan,et al. Resolvin E1 Selectively Interacts with Leukotriene B4 Receptor BLT1 and ChemR23 to Regulate Inflammation1 , 2007, The Journal of Immunology.
[34] G. Hotamisligil,et al. Inflammation and metabolic disorders , 2006, Nature.
[35] Katherine B Percarpio,et al. Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. , 2006, Chemistry & biology.
[36] J. Schwab,et al. Lipoxins and new lipid mediators in the resolution of inflammation. , 2006, Current opinion in pharmacology.
[37] B. Levy,et al. RvE1 protects from local inflammation and osteoclastmediated bone destruction in periodontitis , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[38] Makoto Arita,et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[39] A. Sher,et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1 , 2005, The Journal of experimental medicine.
[40] C. Serhan,et al. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. , 2004, Prostaglandins & other lipid mediators.
[41] A. Sher,et al. Exogenous Pathogen and Plant 15-Lipoxygenase Initiate Endogenous Lipoxin A4 Biosynthesis , 2004, The Journal of experimental medicine.
[42] C. Serhan,et al. Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entrée for resoleomics. , 2004, Rheumatic diseases clinics of North America.
[43] C. Serhan,et al. Novel Docosatrienes and 17S-Resolvins Generated from Docosahexaenoic Acid in Murine Brain, Human Blood, and Glial Cells , 2003, The Journal of Biological Chemistry.
[44] Joachim Spranger,et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. , 2003, Diabetes.
[45] Jilly F. Evans,et al. International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors , 2003, Pharmacological Reviews.
[46] C. Serhan,et al. Resolvins , 2002, The Journal of experimental medicine.
[47] C. Serhan,et al. Lipid-Derived Mediators in Endogenous Anti-Inflammation and Resolution: Lipoxins and Aspirin-Triggered 15-epi-Lipoxins , 2002, TheScientificWorldJournal.
[48] C. Serhan,et al. Mechanisms in anti-inflammation and resolution: the role of lipoxins and aspirin-triggered lipoxins. , 2001, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[49] C. Clish,et al. Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2–Nonsteroidal Antiinflammatory Drugs and Transcellular Processing , 2000, The Journal of experimental medicine.
[50] R. Doms,et al. ChemR23, a putative chemoattractant receptor, is expressed in monocyte‐derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV‐1 strains , 1998, European journal of immunology.
[51] J. Drazen,et al. Antiinflammatory potential of lipoxygenase-derived eicosanoids: a molecular switch at 5 and 15 positions? , 1997, The Journal of clinical investigation.
[52] S. Dahlén,et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. , 1987, Science.
[53] R. Cotran,et al. Mononuclear phagocytes (Kupffer cells) and endothelial cells. Identification of two functional cell types in rat liver sinusoids by endogenous peroxidase activity. , 1972 .
[54] R. Cotran. ENDOTHELIAL PHAGOCYTOSIS: AN ELECTRON-MICROSPOPIC STUDY. , 1965, Experimental and molecular pathology.
[55] BOULIN,et al. [Classification and diagnosis of diabetes]. , 1953, Concours medical.